



Supplementary Fig. 1. Construction of diacylglycerol O-acyltransferase 2 (DGAT2) suppression *in vitro* model. (A) Brief scheme for DGAT2 suppression model via inhibitor and shRNA. (B) Relative DGAT2 expression after shRNA treatments. (C) DGAT2 protein expression in TRCN0000005196 transfection. Asterisk is to indicate non-specific band. (D) BODIPY 493/503 stained lipid droplet after DGAT2 inhibitor PF-06424439 (Pfizer) treatment. (E) Relative intensity of BODIPY after inhibitor treatments. (F) Cellular diacylglycerol (DAG) concentration after DGAT2 suppression. (G) Cellular phosphatidic acid level after DGAT2 suppression. Data represent mean \pm standard deviation. NC, negative control; NS, not significant; shCTR, control shRNA; shDGAT2, DGAT2 shRNA; DAPI, 4',6-diamidino-2-phenylindole. ^a $P < 0.04$, ^b $P < 0.01$, ^c $P < 0.001$, ^d $P < 0.0001$; two-tailed Student's *t*-test.